All In Biotech

Drug Trial Radar · NCT04440982

Feasibility Study of Intraoperative Detection of Residual Cancer in Breast Cancer Patients

Feasibility Study to Evaluate Performance of the LUM Imaging System for Intraoperative Detection of Residual Tumor in Breast Cancer Patients Receiving and Not Receiving Neoadjuvant Therapy

Last checked: Nov 19, 2026Latest source record: Jan 15, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

98

Actual

Start

Sep 1, 2020

Primary completion

Nov 30, 2023

Study completion Feb 29, 2024

Sponsor

Lead sponsor
Lumicell, Inc.Industry
Sponsor type
Industry
Collaborators
National Cancer Institute (NCI)
First posted
Jun 22, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Single (investigator)
Primary purpose
Other
FDA-regulated drug
Yes
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a prospective, multi-center, randomized, clinical trial evaluating patients undergoing breast conserving surgery using the LUM Imaging System.

Conditions

  • Breast Cancer
  • Neoadjuvant Therapy

Interventions

  • LUM015Drug

    LUM015 will be administered 2 to 6 hours prior to surgery for both arms. The LUM Imaging device will be used to assist in the removal of additional tumor tissue in the device intervention arm.

  • Lum Imaging SystemDevice

    UM015 will be administered 2 to 6 hours prior to surgery for both arms. The LUM Imaging device will be used to assist in the removal of additional tumor tissue in the device intervention arm.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Development and validation of tumor detection algorithms in breast cancer patients receiving neoadjuvant therapyTime frame: 1 month
  2. Number of patients with reported adverse eventsTime frame: 14 days
  3. Reduction in residual tumorTime frame: 3 months
  4. Report on patient reported outcomes and patient preference informationTime frame: 12 months

Locations

6 sites in 1 country. Site status is shown where the registry gives one.

  • Stanford Hospital and Clinics

    Palo Alto, California

  • Morton Plant Mease Health Care Oncology Research

    Clearwater, Florida

  • Massachusetts General Hospital

    Boston, Massachusetts

  • Duke Cancer Center

    Durham, North Carolina

  • Novant Health Cancer Center

    Winston-Salem, North Carolina

  • The University of Texas MD Anderson Cancer Center

    Houston, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.